The Food and Drug Administration Antimicrobial Drugs Advisory Committee Meeting voted on Tuesday to recommend authorizing the molnupiravir Covid pill from Merck for high-risk adults. It would be the first in a new class of antiviral drugs that could work against a wide range of variants, including Omicron. Molnupiravir has been shown to modestly reduce the risk of hospitalization and death, predominantly from the Delta, Mu and Gamma variants. The expert panel recommended it for Covid patients who are older … Continue reading “F.D.A. Antimicrobial Drugs Panel Endorse Merck’s Covid Pill Molnupiravir For High Risk Adults.”
Heavily Shorted KemPharm Reports Higher Revenue, Elimination of Debt and FDA Approval For AZSTARYS™ NDA
Pharmaceutical company KemPharm shares have risen after $KMPH received approval for the AZSTARYS NDA an alternative for Adderall and other ADHD treatments. In there fourth quarter earnings they announced a restructured its balance sheet, extinguished its debt and re-listed on The Nasdaq Capital Market. The stock is also heavily shorted.
FDA Approves MacroGenics Drug Margenza For Breast Cancer With Chemotherapy
Biopharmaceutical company MacroGenics Announced Wednesday FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer following Phase 3 clinical trials. Product launch anticipated in March of 2021